T2DM individuals with “high” or “very high” CVD risk should receive anti-diabetic agents with proven CV benefits (GLP-1 RAs and SGLT-2 inhibitors) regardless of their glycemic control status. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.